SLRX Executive Compensation
* In USD (Original Currency)|
Filing Date (SEC Report) |
Year | Reporting Name | Salary | Bonus | Stock Award | Incentive Plan Compensation | Other Compensation | Total |
|---|---|---|---|---|---|---|---|---|
| 2023-05-01 | 2021 | Mark J. Rosenblum Executive Vice President, Finance and Chief Financial Officer | 278,360 | 53,000 | 0 | 99,374 | 11,275 | 442,010 |
| 2023-05-01 | 2022 | Mark J. Rosenblum Executive Vice President, Finance and Chief Financial Officer | 300,000 | 0 | 0 | 97,775 | 12,200 | 494,554 |
| 2023-05-01 | 2021 | David J. Arthur President and Chief Executive Officer | 378,750 | 0 | 0 | 181,800 | 116,205 | 676,755 |
| 2023-05-01 | 2022 | David J. Arthur President and Chief Executive Officer | 500,000 | 0 | 0 | 217,375 | 12,200 | 941,023 |
| 2022-04-28 | 2020 | David J. Arthur President and Chief Executive Officer | 340,000 | 84,500 | 0 | 0 | 106,400 | 1,136,435 |
| 2022-04-28 | 2020 | Mark J. Rosenblum Executive Vice President, Finance and Chief Financial Officer | 265,000 | 56,800 | 0 | 0 | 72,413 | 520,486 |
| 2022-04-28 | 2021 | Mark J. Rosenblum Executive Vice President, Finance and Chief Financial Officer | 378,750 | 181,800 | 0 | 0 | 116,205 | 676,755 |
| 2021-04-27 | 2020 | David J. Arthur President and Chief Executive Officer | 340,000 | 84,500 | 0 | 0 | 106,400 | 1,136,435 |
| 2021-04-27 | 2019 | David J. Arthur President and Chief Executive Officer | 315,000 | 0 | 0 | 0 | 10,500 | 518,238 |
| 2021-04-27 | 2020 | Mark J. Rosenblum Executive Vice President, Finance and Chief Financial Officer | 265,000 | 56,800 | 0 | 0 | 72,413 | 520,486 |
| 2021-04-27 | 2019 | Mark J. Rosenblum Executive Vice President, Finance and Chief Financial Officer | 81,708 | 19,300 | 0 | 0 | 215,160 | 438,287 |
| 2020-04-29 | 2019 | William K. McVicar Former Chief Executive Officer of Flex Pharma, Inc. | 272,956 | 18,253 | 0 | 0 | 0 | 291,209 |
| 2020-04-29 | 2019 | David J. Arthur President and Chief Executive Officer | 315,000 | 192,738 | 0 | 0 | 0 | 507,738 |
| 2020-04-29 | 2019 | Mark J. Rosenblum Executive Vice President, Finance and Chief Financial Officer | 81,708 | 122,119 | 0 | 0 | 0 | 203,827 |
| 2020-04-29 | 2019 | Scott Jordan Former Chief Business Officer | 220,000 | 64,246 | 0 | 0 | 0 | 284,246 |
| 2019-09-18 | 2018 | David J. Arthur | 257,615 | 0 | 0 | 0 | 275,148 | 532,763 |
| 2019-09-18 | 2018 | Scott Jordan | 136,458 | 0 | 0 | 0 | 158,047 | 294,505 |
| 2018-04-23 | 2017 | William McVicar, Ph.D., President, Chief Executive Officer | 325,442 | 0 | 0 | 75,802 | 66,194 | 1,073,898 |
| 2018-04-23 | 2017 | John McCabe, Chief Financial Officer, Treasurer and Secretary | 300,000 | 0 | 0 | 54,000 | 14,121 | 569,664 |
| 2018-04-23 | 2017 | Thomas Wessel, M.D., Ph.D. Chief Medical Officer | 419,056 | 0 | 0 | 75,430 | 15,951 | 766,126 |
| 2018-04-23 | 2016 | Thomas Wessel, M.D., Ph.D. Chief Medical Officer | 406,850 | 0 | 0 | 138,329 | 13,187 | 874,427 |
| 2018-04-23 | 2017 | Katharine Lindemann Former Chief Operating Officer | 184,413 | 0 | 0 | 0 | 194,778 | 610,815 |
| 2018-04-23 | 2016 | Christoph Westphal, M.D., Ph.D., Former President, Chief Executive Officer and Chairman of the Board | 472,770 | 0 | 0 | 200,927 | 27,008 | 1,697,513 |
| 2018-04-23 | 2017 | Christoph Westphal, M.D., Ph.D., Former President, Chief Executive Officer and Chairman of the Board | 245,350 | 0 | 0 | 0 | 78,044 | 355,670 |
| 2017-04-19 | 2016 | Christoph Westphal, M.D., Ph.D. President, Chief Executive Officer, Chair of the Board | 472,770 | 0 | 0 | 200,927 | 15,914 | 1,686,419 |
| 2017-04-19 | 2016 | Robert Hadfield General Counsel and Secretary | 280,000 | 0 | 0 | 79,800 | 13,182 | 616,106 |
| 2017-04-19 | 2016 | Thomas Wessel, M.D., Ph.D. Chief Medical Officer | 406,850 | 0 | 0 | 138,329 | 13,187 | 874,427 |
| 2017-04-19 | 2015 | Thomas Wessel, M.D., Ph.D. Chief Medical Officer | 395,000 | 0 | 0 | 150,100 | 13,182 | 1,716,548 |
| 2017-04-19 | 2015 | Christoph Westphal, M.D., Ph.D. President, Chief Executive Officer, Chair of the Board | 459,000 | 0 | 0 | 218,025 | 19,832 | 696,857 |
| 2016-04-28 | 2014 | Thomas Wessel, M.D., Ph.D. Chief Medical Officer | 4,558 | 55,000 | 0 | 0 | 0 | 59,558 |
| 2016-04-28 | 2015 | Christoph Westphal, M.D., Ph.D., President, Chief Executive Officer, Chairman of the Board | 459,000 | 0 | 0 | 218,025 | 19,832 | 696,857 |
| 2016-04-28 | 2014 | Marina Hahn President, Consumer | 76,154 | 100,000 | 0 | 34,027 | 0 | 913,560 |
| 2016-04-28 | 2015 | Marina Hahn President, Consumer | 340,500 | 0 | 0 | 154,470 | 10,602 | 1,601,742 |
| 2016-04-28 | 2014 | Christoph Westphal, M.D., Ph.D., President, Chief Executive Officer, Chairman of the Board | 337,500 | 0 | 375,804 | 172,603 | 0 | 885,907 |
| 2016-04-28 | 2015 | Thomas Wessel, M.D., Ph.D. Chief Medical Officer | 395,000 | 0 | 0 | 150,100 | 10,432 | 1,713,798 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
